HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) 074856.Supplemental Data All Versions of this Article: clinchem.2006.074856v1 53/1/24    most recent Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Blievernicht, J. K. Articles by Zanger, U. M. Search for Related Content PubMed PubMed Citation Articles by Blievernicht, J. K. Articles by Zanger, U. M. Related Collections Molecular Diagnostics and Genetics

MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide Polymorphisms

¹ Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
² Division of Clinical Pharmacology, University Hospital Tuebingen, Tuebingen, Germany.

^aAddress correspondence to this author at: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstr. 112, 70376 Stuttgart, Germany. Fax 49-(0)711-85-92-95; e-mail uli.zanger{at}ikp-stuttgart.de.

Background: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz. Several nonsynonymous and promoter single-nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with altered hepatic expression and function, which affect drug plasma concentrations.

Methods: We used multiplex PCR to amplify relevant gene fragments while avoiding amplification of the CYP2B7P1 pseudogene. Polymorphic sites were analyzed by allele-specific primer extension followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Method evaluation was performed on a panel of 287 genomic DNA samples previously genotyped by other methods.

Results: Five multiplex assays were developed, comprising the following 15 SNPs: –82TC (*22); 86GC (R29T, *17); 136AG (M46V, *11); 296GA (G99E, *12); 415AG (K139E, *8, *13); 419GA (R140Q, *14); 516GT (Q172H, *6, *7, *9, *13, *19, *20), 547GA (V183I); 769GA (D257N); 785AG (K262R, *4, *6, *7, *13, *16, *19, *20); 983TC (I328T, *16, *18); 1006CT (R336C, *19); 1172TA (I391N, *15); 1282CA (P428T, *21); 1459CT (R487C, *5, *7). In 9 DNA samples showing discrepant genotypes, correctness of the MALDI-TOF MS result was confirmed by direct sequencing.

Conclusions: This genotyping method enabled sensitive, specific, accurate, and comprehensive determination of 15 relevant SNPs of CYP2B6. The assay design allows analysis of SNP subsets, incorporation of additional SNPs, and performance of high-throughput genotyping.

The following articles in journals at HighWire Press have cited this article:

				M. H. Hofmann, J. K. Blievernicht, K. Klein, T. Saussele, E. Schaeffeler, M. Schwab, and U. M. Zanger Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 284 - 292. [Abstract] [Full Text] [PDF]

				J. C.H. Tsang, P. Charoenkwan, K. C.K. Chow, Y. Jin, C. Wanapirak, T. Sanguansermsri, Y.M. D. Lo, and R. W.K. Chiu Mass Spectrometry Based Detection of Hemoglobin E Mutation by Allele-Specific Base Extension Reaction Clin. Chem., December 1, 2007; 53(12): 2205 - 2209. [Abstract] [Full Text] [PDF]